ArticleJournal of virology2020
Identification and Characterization of CD4
Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.The Journal of infectious diseases · 2023Trial
- Rational design of next-generation vaccine adjuvants: From molecular mechanisms to hybrid delivery platforms.Human vaccines & immunotherapeutics · 2026Review
- Comprehensive mapping of human CD4Cell reports. Medicine · 2026Article
- COMBO-RATE: An experimentally validated bioinformatic tool to identify promiscuous HLA restrictions.bioRxiv : the preprint server for biology · 2026Article
- Potent and Long-Lasting Immunogenicity Generated by LNP-mRNA gE Antigen Against Varicella Zoster Virus via an AI-Assisted Pipeline.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- A Review of Cutaneous Viral Infections and Their Potential Role in Neurologic Diseases.Journal of clinical medicine · 2025Review
- Repurposing anti-viral subunit and mRNA vaccines T cell immunity for intratumoral immunotherapy against solid tumors.NPJ vaccines · 2025Article
- Longitudinal single cell profiling of epitope specific memory CD4+ T cell responses to recombinant zoster vaccine.Nature communications · 2025Article
- Article
- Self and parasite-derived peptides selected upon DERAA-bearing HLA-DRB1 alleles activate CD4+ T cells from Chagas cardiomyopathy patients and are associated with ventricular dysfunction.Frontiers in immunology · 2025Article
- PINK1 is a target of T cell responses in Parkinson's disease.bioRxiv : the preprint server for biology · 2024Article
- Pre-existing SARS-2-specific T cells are predicted to cross-recognize BA.2.86.Cell host & microbe · 2024Article
- Tiza-BMJ open · 2023Article
- Targets and cross-reactivity of human T cell recognition of common cold coronaviruses.Cell reports. Medicine · 2023Article
- Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design.Science China. Life sciences · 2023Article
- Unaltered T cell responses to common antigens in individuals with Parkinson's disease.Journal of the neurological sciences · 2023Article
- Targets and cross-reactivity of human T cell recognition of Common Cold Coronaviruses.bioRxiv : the preprint server for biology · 2023Article
- Immunological memory to common cold coronaviruses assessed longitudinally over a three-year period pre-COVID19 pandemic.Cell host & microbe · 2022Article
- Immunological memory to Common Cold Coronaviruses assessed longitudinally over a three-year period.bioRxiv : the preprint server for biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 3 countries.
Funding
Abstract
Infections with varicella-zoster virus (VZV) are associated with a range of clinical manifestations. Primary infection with VZV causes chicken pox. The virus remains latent in neurons, and it can reactivate later in life, causing herpes zoster (HZ). Two different vaccines have been developed to prevent HZ; one is based on a live attenuated VZV strain (Zostavax), and the other is based on adjuvanted gE recombinant protein (Shingrix). While Zostavax efficacy wanes with age, Shingrix protection retains its efficacy in elderly subjects (individuals 80 years of age and older). In this context, it is of much interest to understand if there is a role for T cell immunity in the differential clinical outcome and if there is a correlate of protection between T cell immunity and Shingrix efficacy. In this study, we characterized the Shingrix-specific
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.